Physician profile
Peter Mohai
NPI 1831185966
$12,467.15
in general payments reported to CMS, 2019-2025
33 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $1,537 · 2021: $2,469 · 2022: $2,225 · 2023: $1,960 · 2024: $2,029 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,313.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,371.28 | 2019-2025 | |
| Amgen INC. | $2,139.49 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $1,794.83 | 2019-2025 | |
| Pfizer INC. | $1,142.57 | 2019-2024 | |
| Glaxosmithkline, LLC. | $984.39 | 2019-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $675.58 | 2019-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $522.52 | 2019-2023 | Orencia |
| Horizon Therapeutics Plc | $512.01 | 2019-2023 | Krystexxa |
| Ucb, INC. | $410.41 | 2020-2025 | Bimzelx |
| Aurinia Pharma U.S., INC. | $277.42 | 2021-2024 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $230.32 | 2022-2024 | Saphnelo |
| Genzyme Corporation | $184.98 | 2020-2024 | |
| Lilly USA, LLC | $166.99 | 2019-2022 | |
| Organon LLC | $128.24 | 2021-2025 | Hadlima, Renflexis |
| Genentech USA, INC. | $100.68 | 2024-2025 | Gazyva, Actemra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $100.43 | 2024 | Arcalyst |
| Sobi, INC | $80.50 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $77.76 | 2019 | |
| Tersera Therapeutics LLC | $77.43 | 2022-2025 | Quzyttir |
| Alexion Pharmaceuticals, INC. | $68.04 | 2020-2024 | Strensiq |
| Octapharma USA, INC. | $58.39 | 2025 | Octagam Immune Globulin (Human) |
| Ani Pharmaceuticals, INC. | $46.80 | 2024 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $46.73 | 2024-2025 | Idacio |
| Merck Sharp & Dohme LLC | $44.99 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $38.10 | 2019 | |
| Pacira Therapeutics, INC. | $36.48 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $29.83 | 2025 | |
| Sandoz INC. | $27.20 | 2023 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $24.86 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $21.69 | 2024 | Simlandi |
| United Therapeutics Corporation | $15.84 | 2022 | |
| Si-Bone, INC. | $15.43 | 2022 | |
| Pharming Healthcare, INC. | $14.94 | 2023 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mohai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.